
C1M Biomarker May Predict Joint Damage in Early Arthritis
Higher baseline serum levels of C1M, a biochemical marker of type I collagen degradation, were associated with higher odds of progression of total joint damage in patients with early arthritis at 1 and 5 years; however, the C2M marker showed no association with progression.
METHODOLOGY:
Researchers investigated the association between baseline serum C1M and C2M levels and the radiographic progression of joint damage in a cohort of patients with early undifferentiated inflammatory arthritis and recently developed rheumatoid arthritis (the ESPOIR cohort).
They included 813 patients (mean age, 48.1 years; 76% women) having two or more swollen joints, with the swelling lasting more than 6 weeks but less than 6 months, and no previous use of disease-modifying drugs or steroids.
Radiographs of the hands, wrists, and feet were obtained and scored according to the van der Heijde-modified Sharp score (mSS), assessing erosion, joint space narrowing, and total radiographic scores for each patient; serum C1M and C2M levels were assessed using biochemical assays.
Radiographic progression was defined as an increase from baseline in the mSS score of at least 1 point at 1 year and of at least 5 points at 5 years.
TAKEAWAY:
Baseline serum levels of C1M were 42% higher in patients who had progression of total joint damage at 1 year than in those without progression (median, 68 ng/mL vs 48 ng/mL; P < .0001).
Patients with baseline serum levels of C1M in the highest quartile had increased odds of progression of total joint damage (adjusted odds ratio [aOR], 2.12; P = .03) and bone erosion (aOR, 3.80; P = .005) after adjusting for the Disease Activity Score-28, C-reactive protein levels, and anti-citrullinated protein antibody positivity.
Median baseline serum levels of C1M were 33% higher in patients with progression of total joint damage at 5 years than in those without progression (P = .0037); each ng/mL increase in baseline serum levels of C1M was associated with an increased risk for progression after adjusting for age, sex, and BMI (P = .016).
No significant associations were found between baseline serum levels of C2M and radiologic progression at either 1 or 5 years.
IN PRACTICE:
"[The] biological marker [C1M] may be combined with other biomarkers of disease activity to improve the identification of patients with early arthritis at high risk for progression," the authors wrote.
SOURCE:
This study was led by Patrick Garnero of Inserm, Lyon, France. It was published online on July 10, 2025, in RMD Open.
LIMITATIONS:
At 5 years, radiologic data were available for only 60% of patients, limiting the robustness of the findings. Relationships of C1M and C2M levels with clinical progression were not analysed using the Disease Activity Score-28. Additionally, the effect of treatment groups during follow-up was not considered.
DISCLOSURES:
This study received an unrestricted grant from Merck Sharp and Dohme, with additional support from Inserm to support part of the biological database. The ESPOIR cohort study was supported by the French Society of Rheumatology, Pfizer, Abbvie, Lilly, Fresenius, and Biogen. One author disclosed being an employee of and owning stocks in Nordic Biosciences.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
2 hours ago
- Gizmodo
Non-Hormonal Male Birth Control Pill Passes Key Test
For many couples, the numerous options for birth control still come with plenty of hassles. But scientists are working on an alternative approach that might be more appealing for some: a non-hormonal male birth control pill with possibly very few side effects. The drug is codenamed YCT-529, and it's being developed by the company YourChoice Therapeutics, in conjunction with researchers from the University of Minnesota and others. In early human trial results published this week, YCT-529 appeared to be safe and tolerable. The drug is now being tested in larger-scale studies. Injectable Male Birth Control Effective for at Least 2 Years, Says Biotech Startup YCT-529 (previously known as GPHR-529) targets how the body interacts with vitamin A, which helps maintain fertility in mammals. It blocks a protein that binds to a form of vitamin A (retinoic acid) in our cells, known as retinoic acid receptor alpha (RAR-α). By selectively blocking RAR-α and not other similar proteins, the hope is that YCT-529 will reduce sperm production to zero without causing any major side effects. Importantly, this process is also meant to be reversible once people stop taking the drug. The company began its first clinical trial of YCT-529 in late 2023, and the findings of the trial were published this week in Communications Medicine. It involved 16 healthy men who received either a daily placebo or varying doses of YCT-529; some were also given the drug in combination with food. Phase I trials are primarily intended to test a drug's safety, and YCT-529 seemed to pass with flying colors. Compared to controls, the men on YCT-529 experienced no changes in their heart rate, sex drive, mood, or levels of fertility-related hormones. In fact, no adverse events likely related to the drug were documented at all, the researchers found. There was some evidence that food might slow people's absorption of the drug, though more study is needed to know for sure. 'These results warrant further clinical development of YCT-529,' the study authors wrote. With a New Gel, the Future of Male Birth Control Looks Bright As promising as this data looks, it is still very early days. That said, YourChoice Therapeutics has already forged ahead with a larger Phase II study of YCT-529. And the race to create the world's first reversible male birth control is only heating up. Other research teams and companies have developed contraceptive gels and implants that have also shown promise in human trials so far. Soon enough, men will hopefully have several birth control options to pick from, just like women.
Yahoo
5 hours ago
- Yahoo
French left urges Macron to act over US plan to destroy contraceptives
France's left-wing politicians on Saturday called on President Emmanuel Macron to intervene over US plans to destroy nearly $10 million worth of female contraceptives in Europe, calling it an "affront" to public health. A State Department spokesperson told AFP this week that "a preliminary decision was made to destroy certain" birth control products from "terminated Biden-era USAID contracts." The US Agency for International Development, the country's foreign aid arm, was dismantled by Donald Trump's administration when he returned to office in January, replacing former president Joe Biden. Under the plan, some $9.7 million worth of implant and IUD contraceptives stored in Belgium are reportedly set to be incinerated in France. An open letter signed by French Green leader Marine Tondelier and several female lawmakers called the US decision "an affront to the fundamental principles of solidarity, public health and sexual and reproductive rights that France is committed to defending." In the letter, they urged the French president "not to be complicit, even indirectly, in retrograde policies," saying women's contraception products such as IUDs and implants were intended for "low- and middle-income countries." "Cutting aid for contraception is shameful, destroying products that have already been manufactured and financed is even more mind-boggling," Tondelier told AFP. The Greens urged Macron to request the suspension of the plan "as part of a joint initiative with the European Commission." They also called on him to back humanitarian organisations that say they are ready to redistribute the contraception products. Separately, Mathilde Panot, parliamentary leader of the hard left France Unbowed (LFI) party, also urged Macron and Prime Minister Francois Bayrou to take action. "You have a responsibility to act to prevent this destruction, which will cost lives," she said on X. "These resources are vital, particularly for the 218 million women who do not have access to contraceptive care." The US plan has sparked outrage from global health NGOs, with Doctors Without Borders denouncing the "callous waste." "It is unconscionable to think of these health products being burned when the demand for them globally is so great," said Rachel Milkovich of the medical charity's US office. The State Department spokesperson said the destruction will cost $167,000 and "no HIV medications or condoms are being destroyed." Doctors Without Borders says that other organisations have offered to cover the shipping and distribution costs of the supplies, but the US government declined to sign off. US lawmakers have approved slashing some $9 billion in aid primarily destined for foreign countries. sde-ama-as/ach


Washington Post
5 hours ago
- Washington Post
Scientists discover less invasive way to collect babies' stem cells
Researchers have come up with a less invasive way to collect amniotic stem cells — a development they say could reduce dangers for pregnant women and other pregnant individuals as well as fetuses and help researchers grow cells that can help children born with congenital conditions. Scientists use amniotic stem cells to treat congenital anomalies such as spina bifida and heart defects.